Unveiling the Potential of Cmax f2 Factor Applied to Pilot Bioavailability/Bioequivalence Studies—A Case Study with Pazopanib Drug Products
Sign Up to like & getrecommendations! Published in 2024 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics16121579
Abstract: Background: When companies are uncertain about the potential of a new formulation to be bioequivalent to a Reference product, it is common practice to carry out downsized pilot studies as a gatekeeping in vivo strategy… read more here.
Keywords: methodology; cmax factor; pilot; bioequivalence ... See more keywords